The NEJM publication and strong IPO provide significant validation and financial runway. Monitor for Phase 3 initiation details and enrollment updates for onzotrigine and LTG-321, which are the next key catalysts. The stock is likely to trade on pipeline execution rather than quarterly financials.
Price Chart
Executive Summary
Latigo Biotherapeutics reported Q2 2026 results with a net loss of $25.8M (EPS -$27.59 vs consensus -$0.46, a mechanical miss due to tiny share count) and no revenue. The key catalysts are the NEJM publication of positive onzotrigine abdominoplasty results and the completion of an upsized $397.4M IPO, extending cash runway into 2029. Pipeline progress includes planned Phase 3 initiation for onzotrigine and Phase 2 initiation for LTG-321, both with topline results expected in H2 2027.
Key Financial Metrics
Key Facts
- NEJM published positive onzotrigine abdominoplasty trial results meeting primary endpoint with high statistical significance
- Completed upsized IPO raising $397.4M gross proceeds, extending cash runway into 2029
- Plan to initiate Phase 3 bunionectomy and open-label safety trials for onzotrigine in H2 2026; topline results expected H2 2027
- Initiated Phase 2 trial of LTG-321 in osteoarthritis knee; topline results expected H2 2027
- Cash and cash equivalents were $55.0M as of June 30, 2026, before IPO proceeds
Financial Impact
Net loss of $25.8M in Q2 2026, unchanged YoY; no revenue. IPO adds $397.4M gross to balance sheet.
Risk Factors
- Clinical trial failure or delays in Phase 3 for onzotrigine or Phase 2 for LTG-321
- Competition from other non-opioid pain therapies
- Dilution from IPO already completed; no near-term financing risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3356237 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 7w ago | Press Release | $23.04 $23.73 | ▲ +2.99% | ▲ +3.54% | $15.26 (−33.77%) |
Aug 12, 2026 10w ago | 3 | $19.38 $20.06 | ▲ +3.54% | ▲ +2.84% | $15.26 (−21.24%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.26 (−17.60%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.26 (−17.60%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.26 (−17.60%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.26 (−17.60%) |
Aug 10, 2026 11w ago | 8-K | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.26 (−17.60%) |
Aug 7, 2026 11w ago | EFFECT | $18.25 $18.56 | ▲ +1.70% | ▲ +1.73% | $15.26 (−16.38%) |
Aug 6, 2026 11w ago | 3 | $18.25 $18.56 | ▲ +1.70% | ▲ +1.73% | $15.26 (−16.38%) |
Aug 6, 2026 11w ago | 3 | $18.25 $18.56 | ▲ +1.70% | ▲ +1.73% | $15.26 (−16.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers